Curocell
Manufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Select One 48 Yuseong-daero 1184beon-Gil...Phone Number
+82 428633698Website
www.curocellbtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Curocell
Curocell is a leading company in the development of innovative immune cell therapies for cancer treatment. Utilizing genetically modified immune cells, the company aims to provide hope to numerous cancer patients by overcoming the limitations of existing therapies. Curocell is committed to producing reliable advanced pharmaceuticals in state-of-the-art GMP facilities. The company is focused on evolving its technology to target various types of cancer, thereby expanding its impact in the field of oncology.Explore more
Curocell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curocell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Curocell is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Curocell
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Curocell has recently received funding, and reach out quickly before it becomes old news!
Curocell, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Curocell recently announced quarterly report
Product Launch: Get notified when Curocell launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Curocell has new funding data
Click to see if Curocell had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Curocell as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Curocell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curocell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curocell.
Curocell Tech Stack
A closer look at the technologies used by Curocell
See more technologies
Curocell News & Media
GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T Therapy
SEOUL, South Korea--(BUSINESS WIRE)--On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration. This partnership will broaden the strategic cooperation between the two companies to encompass the entire project, including the development, production,Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T
Anbal-cel argeting DLBCL completes phase 2 trial Anticipation growing over Korea's first CAR-T therapy ahead of regulatory review Commercial manufacturing scheduled in 2025 at Korea's only CAR-T GMP facility DAEJEON, South Korea, Nov. 1, 2023 /PRNewswire/ -- Curocell, South Korea based CAR-T specialized company (CEO: Gunsoo Kim), has completed Phase 2 clinical trial for its next-generation CD19 CAR-T therapy "Anbal-cel" that targets relapsed or refractory DLBCL (Diffuse Large B-cell Lymphoma). TCurocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively....Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEON, South Korea, June 20, 2023 /PRNewswire/ -- Curocell Inc, a Korea-based clinical-stage CAR-T cell therapy company, announced updated Phase 2 interim results for Anbalcabtagene-autoleucel (anbal-cel) on June 15
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curocell
Sign Up For FreeTo access detailed company insights
Curocell is a leading company in the development of innovative immune cell therapies for cancer treatment. Utilizing genetically modified immune cells, the company aims to provide hope to numerous cancer patients by overcoming the limitations of existing therapies. Curocell is committed to producing reliable advanced pharmaceuticals in state-of-the... Read More
